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Abstract
Purpose—The role of pharmacogenomics, clinical and demographic parameters in
pharmacokinetic predictions was evaluated in patients receiving mycophenolic acid (MPA).
Methods—A cohort study design of patients with glomerulonephritis secondary to lupus
nephritis and anti-neutrophil cytoplasmic antibody (ANCA) vasculitis was employed. Forty-six
patients with lupus nephritis and ANCA vasculitis who were receiving MPA were recruited from
the nephrology clinic. The study assessed the relative single and combined roles of genomic,
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clinical, and demographic characteristics on pharmacokinetic parameters using general linear
models. The study focused on polymorphisms in UGT1A7, UGT2B7, and ABCB1/MDR1; all of
which have limited data available concerning MPA pharmacokinetics. All patients had
pharmacokinetic assessments for MPA and glucuronide metabolites (MPAG, AcMPAG).
Genotyping was performed for known variants of UGTs (UGT1A9, UGT1A7, UGT2B7), and
multidrug resistance protein (ABCB1/MDR1), involved in MPA disposition. Analyses included
univariate and multivariate linear modeling.
Results—In univariate analyses, UGT2B7 heterozygosity (coefficient 0.3508; R2=0.0873) and
UGT1A7 heterozygosity (coefficient 0.3778; R2=0.0966) predicted increased apparent oral
clearance of MPA. UGT1A7 heterozygosity (coefficient −0.4647; R2 0.0897) predicted lower
MPA trough concentrations. In multivariate assessments, higher urinary protein excretion, lower
serum creatinine, and increased weight predicted greater apparent oral clearance of MPA (p<
0.0001). White race and higher serum creatinine predicted higher MPA trough concentrations
(p<0.0001). Higher exposure to MPA was predicted by decreased urinary protein excretion and
increased serum creatinine.
Conclusions—Clinical and demographic parameters were 2–4 times more important in MPA
disposition than genotypes and explained 30–40% of the pharmacokinetic parameters.
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Introduction
Autoimmune-related kidney diseases such as systemic lupus erythematosus (SLE) and anti-
neutrophil cytoplasmic antibody (ANCA) small vessel vasculitis (SVV) are treated with
myriad drugs approved for use in the transplant and cancer populations. These treatments
commonly include but are not limited to mycophenolate mofetil/sodium, glucocorticoids,
and cyclophosphamide. Treatments with these drugs are considered “off-label” with respect
to Food and Drug Administration (FDA) labeling. Intrinsic to off-label usage is the
uncertainty pertaining to the effects of disease-related clinical covariates on drug disposition
(pharmacokinetics). Patients with glomerulonephritis can have reductions in serum albumin
and kidney function (glomerular filtration rate [GFR] or estimated creatinine clearance
[eClCr]), and elevations in proteinuria, all of which may alter drug disposition. Kidney
transplant patients, on the contrary, have primarily reductions in GFR and less commonly
alterations in serum albumin and urinary protein excretion. Reductions in serum albumin
may increase clearance through metabolism and excretion by increasing the unbound drug.
Increases in urinary protein excretion may increase excretion through clearance of the bound
drug. Among the various forms of glomerulonephritis, there can be a predilection for
patients of certain ages, races, and genders; factors that may result in variable drug
disposition. For drugs such as mycophenolic acid (MPA), the active moiety of
mycophenolate mofetil and mycophenolate sodium, there is inherently wide inter-individual
variability in pharmacokinetics. [1, 2] Hence, the alterations in clinical and/or demographic
covariates in the glomerulonephritis population compared with the kidney transplant
population could lead to variability in pharmacokinetics above and beyond that which would
be predicted from studies employing the latter patients.
There are several reports in transplant and healthy normal populations that suggest altered
MPA pharmacokinetics secondary to single nucleotide polymorphisms (SNPs) in the uridine
glucuronosyltransferase metabolizing enzymes (UGTs) [3–8]. Polymorphisms in the
UGT1A9 gene and influence on MPA have been most frequently described. The UGT1A9
T-275A and C-2152T promoter SNPs have been associated with enhanced metabolism of
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mycophenolic acid [3, 8]. UGT1A9 SNPs at nucleotide base positions 8 and 98 have been
associated with enhanced exposure to MPA, suggesting a reduction in metabolism. Less
well described are the effects of polymorphisms in the UGT2B7 gene, with one report
describing an increase in MPA exposure in patients with the UGT2B7 C802T variant [3].
Several limitations exist for these published pharmacogenomic reports. The studies
comprised mostly Caucasian and Asian populations and therefore generalizability to patients
of other ethnic subpopulations receiving MPA may be limited. Also, there is not always
consistency in results between in vitro and in vivo approaches; reduced intrinsic clearance
was noted in an in vitro evaluation of the effects of UGT1A8 *2 and *3, while in vivo
studies showed a lack of effect by UGT1A8 variants on MPA disposition [3, 5, 7]. In
addition to polymorphisms in drug-metabolizing enzymes, it is known that polymorphisms
in the ABCC2 gene, which encodes the multidrug resistance-associated protein MRP2, can
influence the disposition of MPA [9, 10]. There are more limited data that suggest that
polymorphisms in the multidrug resistance transporter gene ABCB1 or MDR1 may also
influence the disposition of MPA [11, 12]. These studies support the need to evaluate SNP
frequencies within the populations of specific glomerular diseases and within patient
demographic subpopulations to understand the contribution of pharmacogenetics as opposed
to the effects of demographics or clinical covariates on variability in MPA
pharmacokinetics.
In this study, we investigated the ability of genomic, clinical, and demographic patient
characteristics to predict the pharmacokinetic outcomes of MPA (bound and unbound) and
its phenolic- and acyl-glucuronide metabolites (MPAG and AcMPAG) in patients with
glomerulonephritis secondary to SLE and ANCA SVV using linear statistical models. In
order to expand on the existing knowledge of MPA and pharmacogenomics, we focused on
the less well-described influence of polymorphisms in UGT2B7, UGT1A7, and ABCB1
genes, but also sought to characterize the influences of UGT1A9 genes in
glomerulonephritis. We hypothesized that genetic variations in UGT2B7 and UGT1A7, and
in ABCB1 contribute to the disposition of MPA and its glucuronidated metabolites. We also
explored the separate and combined contributions of the pharmacogenomic, disease-related,
and demographic patient characteristics to the prediction of the disposition of total MPA,
unbound MPA, and the glucuronide metabolites MPAG and AcMPAG.
Materials and methods
Research subjects
Patients with biopsy-confirmed SLE or ANCA SVV with kidney manifestations who were
receiving maintenance therapy on a stable dose of MPA (Cellcept®; Roche, Nutley, NJ,
USA) for at least 2 weeks were evaluated for enrollment. MPA dosing regimens were
prescribed by the treating nephrologists and ranged from 250 mg twice daily to 1,500 mg
twice daily. The patients participated in a 24-h MPA pharmacokinetics evaluation approved
by the Biomedical Institutional Review Board and conducted in the inpatient clinical
research center. Specific details of these studies and results from noncompartmental
pharmacokinetics for MPA and AcMPAG were previously described [13, 14]. Briefly, blood
samples were collected at times 0, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, and 24 h and urine was
collected from 0–6, 6–12, and 12–24 h. Plasma and urine samples were assayed for MPA
and MPAG by high-performance liquid chromatography (HPLC) with ultraviolet detection
assay [15]. Plasma and urine standard curves for MPA were linear over the range of 0.2–200
μg/mL and 1–50 μg/mL respectively. Plasma and urine standard curves for MPAG were
linear over the range of 1–200 μg/mL and 5–1,500 μg/mL respectively. The AcMPAG
metabolite was assayed in plasma and urine by liquid chromatography/ mass spectrometry
(LC/MS) developed in the laboratory. Tuning, operation, peak integration, and data analysis
were performed in negative ion mode using multiple reaction monitoring (Analyst software
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v.1.4.1; Applied Biosystems). Reverse phase separation (gradient elution using 0.1% acetic
acid aqueous phase and 100% acetonitrile organic mobile phase) was accomplished using a
Zorbax RX-C8 150×2.1 mm column with a 5-μm particle size (Agilent Technologies, Santa
Clara, CA, USA). Analysis required a 10-μL injection and a solvent flow of 0.3 mL/min.
Total run time, including equilibration, was 15 min per injection. The internal standard was
azidothymidine. Plasma and urine standard curves for AcMPAG were linear over the range
of 0.01–50 μg/mL and 1–500 μg/mL respectively. Unbound plasma fraction was determined
by filtration via a Centrifree® Micropartition device (Millipore, Cork, Ireland) with a filter
cut-point of 30,000 Da. Unbound concentrations were calculated as unbound fractions
multiplied by total concentrations.
Clinical data were abstracted from medical charts and included serum creatinine (SCr),
estimated creatinine clearance (eClCr) by Cockcroft and Gault [16], urinary protein to
creatinine ratio (UP:Cr), serum albumin, and steroid dose. Abstracted demographic data
included age, weight, race, and gender.
Genotyping assessments
A 5-mL whole blood sample was collected into an EDTA-containing vacutainer and
genomic DNA was isolated using a Flexigene Qiagen kit (Qiagen, Valencia, CA, USA).
Genotyping was conducted for several published UGT1A9, UGT1A7, and UGT2B7 SNPs
reported to result in alterations in MPA metabolism (Table 1) [3–5, 7, 8]. Additionally,
ABCB1/ MDR1 polymorphismss were evaluated secondary to published data, suggesting
the role of the P-glycoprotein transporter in MPA disposition (Table 1) [11]. Genotyping
assessments for UGT1A7 T622C (c___287260_10; Applied Biosystems, Foster City, CA,
USA) and MDR1 C1236T (c___7586662_10; Applied Biosystems) were conducted using
commercially available assays. Genotyping for UGT1A9 C98T, UGT1A9 T-275A, and
MDR1 C3435T was conducted using custom assays manufactured by Applied Biosystems.
Allelic discrimination was assessed for all Applied Biosystems products using 5 μL of
TaqMan Universal PCR Master Mix, No AmpErase UNG (×2; Applied Biosystems), 0.25
μL (of 40× assay) or 0.5 μL (of 20× assay), 10–20 ng genomic DNA and a total reaction
volume of 10 μL as per the manufacturer’s instructions. The reactions were cycled with an
initial denaturation of 95°C for 10 min followed by 50 cycles of 92°C for 15 seconds, and
then 60°C for 1.5 min on an Applied Biosystems 7900 Taqman PCR instrument. Prior to
conducting the allelic discrimination reactions, a subset of samples were sequenced using
the primers noted in Table 2 in order for them to serve as positive controls for the former
assays. Genotyping for UGT1A9 G8A, UGT1A9 C-2152T, and UGT2B7 C802T was
conducted by Polymorphic DNA Technologies (Alameda, CA, USA). All genotyping results
were coded as 0 (wildtype/ wildtype), 1 (heterozygote), or 2 (variant/variant).
Statistical analysis strategy and methods
Descriptive statistical methods were applied to the pharmacokinetic, demographic, clinical,
and genotype data. Graphical visualization of the data and summary tabulations of
frequencies, means, standard deviations, and ranges were evaluated. Each of the
pharmacokinetic outcome variables was transformed to natural log (ln scale) prior to use in
the statistical computations. The observed genotype frequencies for each defined locus were
used in a Chi-squared test procedure for the testing of deviation from the Hardy–Weinberg
equilibrium.
Putative relationships between pharmacokinetic outcomes and patient characteristics were
explored using descriptive methods (e.g., estimation of Spearman’s correlation coefficients),
linear models for natural log (ln) scale pharmacokinetic variables, hypothesis testing, and
exploratory model-building methods (e.g., stepwise variable selection algorithms, all
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possible regressions, etc.). For these analyses a set of pharmacokinetic outcome variables of
interest for total MPA, unbound MPA, MPAG and AcMPAG was selected.
The clinical and demographic patient characteristics of interest included serum albumin,
UP:Cr, eClCr, weight, age, race, gender, and glucocorticoid dose. Since patients of various
races participated in the study, race was coded as Caucasian (1) vs NonCaucasian (2) for
analyses. The genotypes of interest focused on the allelic variation at each of the targeted
SNP loci: UGT1A9 G8A, C98T, C-2152T, T-275A, UGT2B7 C802T, UGT1A7 T622C, and
ABCB1/MDR1 C1236T and C3435T. Genotypes were coded as 0 (wildtype), 1
(heterozygote), or 2 (homozygous variant). In cases of the minimal numbers of the “2” code,
assessments included only 0 and 1.
Following descriptive graphical examinations of the relationships between the ln
pharmacokinetic outcomes (lnPK) and the various patient characteristic variables, simple
univariate models were fitted for each of the lnPK variables conditional on the selected
clinical, demographic or genotype variable. Univariate relationships with p values <0.05
were employed in building multivariate models. Next, the combined set of genotype,
clinical, and demographic variables was used to fit various multivariable linear models for
the lnPK outcomes via the application of variable selection algorithms (e.g., stepwise
selection, backward elimination, etc.) For each lnPK variable, a final model was selected
based on considerations of the statistical significance of the candidate predictor variables
and the overall model R2.
Auxiliary analyses were also performed to evaluate the plausibility of assumptions made
(e.g., analysis of residuals) and to evaluate the sensitivity of the results to reasonable
perturbations of the methods used. All statistical computations were performed using SAS
System software (Version 9.1; SAS Institute, Cary, NC, USA).
Results
Demographic and clinical data (Table 3) and noncompartmental pharmacokinetic data for
MPA, MPAG, and acyl-MPAG (Table 4) were available for 27 SVV patients and 19 SLE
patients. AUC6–12 /AUC 0–12 was used as a measure of enterohepatic recycling as
demonstrated by others [3, 8]. The racial distribution of these 46 patients was 59%
Caucasian, 28% African–American, and 13% Other (Asian [n=3], Native American [n=2],
not specified [n=1]). Sixty-seven percent of study participants were female. At the time of
the pharmacokinetic analysis, these subjects exhibited a wide range of clinical laboratory
parameters: eClCr (18.3 to 185 mL/min), UP:Cr (0.0 to 7.9), and serum albumin (26 to 52 g/
L). The frequency data for UGT and ABCB1/MDR1 genotypes in the evaluated SVV
vasculitis and SLE nephritis patients are provided in Table 5. All SNP frequencies were in
Hardy–Weinberg equilibrium. The frequencies for the UGT1A9 polymorphisms were too
low to be able to incorporate them into any planned univariate and multivariate model
assessments.
Analyses of univariate models for the lnPK outcomes were performed to evaluate the
separate predictive value of genotype, clinical, and demographic patient characteristics. The
univariate models with p<0.05 are summarized in Table 6. The coefficient gives an estimate
of the direction and magnitude of the changes in the outcomes based on the level of the
dependent variable. For those models evaluating only clinical and demographical factors, the
fit (R2) ranged from ~0.10 to ~0.32. Notable contributors (R2 ~0.20 to 0.32) to MPA trough
concentrations, exposure (AUC), and oral clearance were kidney function measures (Scr and
eClcr). The eClcr was positively related to unbound MPA oral clearance and negatively
predictive for MPA AUC. This appears consistent with the relationship between unbound
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drug and glomerular filtration rate on renal clearance, e.g. increased unbound drug,
increased losses through renal clearance by filtration. The small value for the coefficient
mirrors the fact that usually only 3% of a MPA dose is eliminated by the kidneys [17].
Urinary protein and serum albumin were moderate contributors (R2~0.13) to MPA and
metabolite disposition. Demographic factors (age, race, weight) and glucocorticoid dose
were less contributory (R2 ~0.10) to the disposition of MPA and MPAG. However, age
contributed ~20% toward the exposure (AUC 0–12 and AUC 6–12) of AcMPAG, e.g.,
increased age led to increased exposure. Genotype factors were generally less contributory
(R2=0.09) to MPA disposition. Genotypes for UGT1A7 (T622C) and UGT2B7 (C802T)
appeared to be predictive of MPA oral clearance, exposure (AUC), and maximal plasma
concentration. The UGT2B7 C802T heterozygote predicted increased renal clearance of
MPA (R2=0.1974) and AcMPAG metabolite and decreased MPA AUC0–12, AUC6–12, and
increased oral clearance. The homozygous variant genotype for UGT2B7 C802T was
predictive of increased MPA AUC 6–12 and decreased renal clearance of MPA (R2=0.0897).
The UGT1A7 heterozygote was predictive of increased MPA oral clearance and decreased
maximal plasma concentration. The homozygous variant for the UGT1A7 occurred in only
one patient, so the contribution of this SNP to MPA disposition was not able to be assessed.
The ABCB1/MDR1 SNPs were not found to significantly predict lnPK variables in the
univariate assessments.
The clinical, demographic, and genotype variables from univariate models in Table 5 were
assessed in multivariate models to predict the combined influence of these parameters on
pharmacokinetics (Table 6). The goodness of fit of the models conditional on all variables
(clinical, demographic, and genotype) was generally much better than the goodness of fit of
the models conditional on clinical, demographic, or genotype variables alone. For MPA, a
higher UP:Cr and lower SCr appeared to be predictive of increased oral clearance. One
model incorporated weight as a significant variable in predicting oral clearance, improving
the fit of the model R2 from 0.3526 to 0.4397. A lower UP:Cr and higher SCr were
predictive of increased AUC0–12 (R2=0.3622) and AUC 6–12 (R2=0.4931), which is
consistent with the reciprocal relationship between oral clearance and AUC. White race and
higher SCr were both predictive of an increased MPA trough plasma concentration
(R2=0.4244). The multivariate model for renal clearance (R2=0.2763) incorporated both
weight and UGT2B7 genotype. This latter model was the only multivariate assessment that
incorporated a genotype variable.
The significant multivariate relationships observed for the MPAG metabolite included AUC
and renal clearance. Increased serum creatinine and Caucasian race were predictors of
increased AUC 0–12 (R2=0.2950) and AUC 6–12 (R2=0.3420). Additionally, decreased Scr
and female gender were predictors of increased renal clearance (R2=0.2636). MPAG is
primarily eliminated by the kidneys and clearance is inversely related to AUC, so it is
predictable that Scr would influence both AUC and renal clearance.
Similar to MPAG, renal function (Scr or eClcr) was also important in predicting the
AcMPAG AUC and renal clearance. Increased AUC 0–12 was predicted by Caucasian race
and decreasing eClCr (R2=0.4542), while AUC 6–12 was predicted by increased age and Scr
(R2=0.4092). Both decreased serum albumin and Scr were predictive of increased AcMPAG
renal clearance (R2=0.4239).
Discussion
In this study, we sought to characterize the roles of clinical and demographic factors in
glomerulonephritis, as well as genomic alterations in selected UGTs (1A9, 1A7, and 2B7)
and ABCB1/MDR1, in the pharmacokinetics of MPA and its glucuronide metabolites
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MPAG and AcMPAG using linear models. This research was conducted since MPA is often
used in an off-label indication for the treatment of autoimmune-mediated
glomerulonephritis. When drugs are used off-label in patient populations that are different
from where the drug was originally approved, there is a potential for pharmacokinetic
alterations that may require dosing changes to enable an appropriate exposure (AUC),
optimizing outcomes and minimizing adverse effects. This is particularly relevant for
glomerulonephritis where, unlike kidney transplant patients, primarily with decreases in
GFR, glomerulonephritis patients can have reductions in GFR in addition to decreases in
serum albumin and increases in urinary protein excretion. Previous reports by our research
team suggested altered MPA oral clearance in patients with lupus nephritis and ANCA-
associated vasculitis [13, 14], as opposed to what was previously reported for kidney
transplant recipients [17, 18]. In smaller patient populations employing less sophisticated
statistical analyses, we found that nonwhite race [14] (for SVV patients), and decreased
serum albumin [13] (for SLE nephritis patients) favored increases in oral clearance.
However, we also reported an overall reduction in the metabolic capacity (e.g., metabolic
ratio; MPAG AUC/MPA AUC) in the glomerulonephritis patients [13, 14] compared with
kidney transplant recipients. Our current study of an expanded population of
glomerulonephritis patients found relevant alterations in MPA pharmacokinetics influenced
by clinical covariates and pharmacogenomic factors. This study is novel as it describes these
former interactions in a glomerulonephritis population and seeks to elucidate the relative
contribution of each factor on pharmacokinetics. Additionally, this study evaluated the
influence on MPA pharmacokinetics of less well-described polymorphisms in UGT2B7,
UGT1A7 and ABCB1/MDR1. The resultant multivariable models explained 30–50% of the
pharmacokinetic outcomes of MPA. Genomic factors alone explain about 10% of the
pharmacokinetic outcomes MPA.
Our current cohort of 46 patients with glomerulonephritis represented a spectrum of
laboratory abnormalities that would be typical in patients with these disorders, i.e., some
patients with mild disease and others with moderate to severe manifestations. The study
population was hence broad enough in the clinical manifestations of the glomerular disease
to be able to make inferences about the effects of the disease parameters on the
pharmacokinetics of MPA and its glucuronide metabolites. Our regression results (Tables 6,
7) suggested a primary importance of kidney function, through either SCr or eClcr, for the
prediction of most pharmacokinetic parameters for MPA and its metabolites. This finding is
important as it reminds clinicians to be mindful of the effects of kidney disease on the
disposition of drugs such as MPA, which are not readily eliminated unchanged by the
kidneys. It is consistent with suggestions by others [19], that drug metabolism and transport
derangements, among other unknown effects, occur in kidney disease, and these effects can
alter the pharmacokinetics of drugs. In addition to kidney function, UP:Cr also contributed
toward the prediction of the pharmacokinetics of MPA and its metabolites. An elevated
UP:Cr predicted reduced exposure (AUCs) and increased oral clearance for MPA. Two
previous publications by our group also highlight the need to be cognizant of the effects of
UP:Cr and/or serum albumin on the pharmacokinetics of highly bound drugs, particularly
when assessing total drug concentrations [13, 20]. According to multivariate regression data
from the present study, an increase in UP:Cr from 0.5 to 3.5 at a stable SCr of 2 mg/dL
(176.8 mol/L) would result in a MPA AUC0–12 decrease of 25 units (from 76 μg · h/mL to
51 μg · h/mL). Similarly, at a stable UP:Cr of 0.5, an increase in SCr from 2 mg/dL to 5 mg/
dL (176.8 mol/L to 442 mol/L) would result in a tripling of the AUC0–12 (from 76μg · h/mL
to 228 μg · h/mL).
The glomerulonephritis study population reported here included mostly Caucasian and
African–American patients (59% and 28% respectively), but relatively few patients of other
races to enable ascertainment of a multitude of race-related effects on MPA disposition.
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Caucasian race was predictive of higher MPA trough concentrations, and higher exposure
(AUC) to the metabolites MPAG and AcMPAG. Our results contrast with data from the
kidney transplant literature that have not reported associations between race and MPA
disposition [21, 22]. Our multivariate regression results show that at a stable SCr of 2 mg/dL
(176.8 mol/L), Caucasian patients have a 2-fold higher Ctr concentration than non-
Caucasians. Within Caucasian patients, a doubling of SCr would result in an 8-fold increase
in Ctr concentration.
Female subjects were adequately represented in our study (67%), but have historically been
under-represented in biomedical research. Our results suggest that female gender may
predict a higher renal clearance of the MPAG metabolite. Since SCr was also contributory to
increased renal clearance in the linear regression model, our data suggest that either there
exists an added effect of female gender on top of the effect of decreased SCr on MPAG
renal clearance and/or there is an interaction between decreased SCr and female gender.
Since it is generally assumed that female subjects have a lower SCr value for level of kidney
function compared with males, the latter explanation may be warranted. However, the
MPAG metabolite is a known substrate for the multidrug resistance-associated proteins
(MRPs) [23] and this transporter is located in the kidney tubules. Previous animal data (rats)
suggest increased liver expression and increased activity of MRP2 in females as compared
with males [24, 25], and this differential activity of MRP2 may also explain the gender-
related influence on renal clearance of MPAG.
Four SNPs in three genes were evaluated in glomerulonephritis patients to assess their role
in the disposition of MPA and its metabolites. The specific SNPs were selected based on
their hypothesized, yet limited in vivo data on their influences on human MPA
pharmacokinetics [3, 4, 26]. Additionally, previous research has established that UGT1A7,
UGT1A9, and UGT2B7 have significant catalytic activities for MPA [1, 27–30]. UGT2B7
C802T has been purported to result in 25% increases in total AUC and 48% increases in
unbound AUC for MPA, as well as increases in maximal plasma concentrations and urinary
AcMPAG. [3, 4, 26]. Our univariate models employing only genotypes showed increased
recycling (AUC6–12) and decreased renal clearance for MPA in the variant homozygous
group. These results seem consistent with the previous publications. Increased oral
clearance, decreased AUC 0–12 and AUC 6–12, and increased renal clearance were
demonstrated in patients exhibiting heterozygosity for UGT2B7 C802T. Increased
AcMPAG renal clearance was also demonstrated in the UGT2B7 heterozygous group. An
increase in MPA renal clearance may be a reflection of a reduction in the renal clearance of
AcMPAG. The finding of a decrease in MPA AUC0–12 in the heterozygous group cannot
currently be explained, but may be due to the intermediate effect of this genotype and its
greater frequency compared with the homozygous variant. In the multivariable models,
UGT2B7 heterozygosity was the only genetic factor remaining, where it predicted increased
MPA renal clearance. A recent study has described the expression of UGT2B7 in the kidney
[31], suggesting a greater contribution of the metabolic enzyme toward the renal clearance
of MPA through its metabolites. Regarding the UGT1A7 T622C SNP, a previous study in
Japanese patients failed to detect any MPA pharmacokinetic alterations [6]. A recent review
publication by Knights and Miners [30] describes the expression of UGT1 and UGT2
protein in human kidney tissues, with positive expression of UGT1A7 described. A major
issue toward determination of specific UGT proteins in tissues is related to the availability
of specific antibodies. Widespread use of absolute quantitative LC/MS methodologies
should help to confirm the absolute amounts of UGTs, including 1A7 in various human
tissues. These data will provide a more definitive assessment regarding the contribution of
specific tissues to the metabolism of MPA. In our univariate assessments analyzing only
genotype variables, heterozygosity of the UGT1A7 variant contributed toward increased oral
clearance and decreased maximal plasma concentration values. While there are currently no
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human studies demonstrating the effects of the ABCB1/MDR1 polymorphism on MPA
pharmacokinetics, an animal study in ABCB1/MDR1-deficient mice suggests the possibility
of increased MPAG concentration when the activity of this protein is low [11], suggesting
decreased export function and resulting in decreased clearance. We failed to detect any
effects of ABCB1/MDR1 C1236T and C3435T on the alteration of the systemic
pharmacokinetics of MPA, suggesting a minimal to absent role of this transporter on MPA
pharmacokinetics.
Although the current study’s findings demonstrated moderate effects of clinical and
demographic variables and minimal effects of UGT1A7 and UGT2B7 genotypes on
explaining the disposition of MPA and its metabolites, the overall effects of these former
genotypes should not be discounted secondary to limitations in the study. The main
limitation surrounds the limited number of patients who contributed to the homozygous
variant genotype groups. Employing a larger population of patients, perhaps by attempting
to select study patients based on specific genotypes may have enhanced the evaluation of the
effects of various genotypes on MPA pharmacokinetics. Regarding UGT1A7 T622C, only
one patient was classified as a homozygous variant, limiting our ability to fully evaluate the
potential impact of this genotype on MPA pharmacokinetics. Our assessments surrounding
the UGT1A7 SNP encompassed the homozygous wildtypes and heterozygotes. Since
heterozygotes in drug-metabolizing gene SNPs often have less alteration in function than
homozygous variants, the differences in the pharmacokinetic variables between these groups
may be more difficult to detect in smaller studies. The numbers were somewhat less limited
for UGT2B7 genotype assessments where a total of 10 patients were included in the
homozygous variant group. Similarly, the ABCB1/MDR1 homozygous variants at
nucleotide base positions 1236 and 3435 were represented by only 4 and 5 patients
respectively, also limiting the ability to evaluate the full role of this covariate in MPA
pharmacokinetics. We did not evaluate the influence of genetic variations in additional
efflux transporters such as ABCC2, since previous studies have evaluated for alterations in
MPA disposition. While the patients in this study represented a fairly broad range of
laboratory values for UP:Cr and serum albumin, they were primarily representative of
patients with mild to moderate forms of glomerulonephritis. It is conceivable that more
acute and/or severe forms of glomerulonephritis might have additional alterations in MPA
disposition. Lastly, as we have assessed numerous pharmacokinetic variables in our patients,
larger studies will be needed to validate the most relevant clinical findings of the current
study.
Conclusions
The results from this study demonstrated the potential importance of factoring in clinical and
demographic variables when assessing the disposition of drugs such as MPA in patients with
glomerulonephritis. In this glomerulonephritis cohort, the predictive value of clinical and
demographic covariates, especially kidney function (eClcr and Scr), urinary
protein:creatinine ratio, serum albumin, and race were more profound than that of the
UGT1A7, UGT2B7, and ABCB1/MDR1 genotypes on MPA pharmacokinetics. The former
covariates explained 2–4 times more of the variability in the pharmacokinetic variables of
MPA than did the genotype covariates. Our data suggest the need for further research and
larger pharmacogenomic studies in glomerulonephritis to adequately assess the contributions
of genetics- and disease-related perturbations to MPA metabolism and transport.
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Table 1
Single nucleotide polymorphisms (SNPs)









MDR, multidrug resistance; UGT, uridine diphosphate glucuronosyltransferase
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Table 2
Sequencing and polymerase chain reaction (PCR) primers
Primer pair Location Sequence (5′-3′)
1 UGT1A9 G8A and C98T F-CCTGCTCTCAGCTGCAGTTCTCT
R-CTTCACTGTGCAATTCAGTGATCTT
2 UGT1A9 C-2152T F-GTAGGTCTTTTACATTTCC
R-CCTGAAACAGCAAAACCAA
3 UGT1A9 T-275A F-TTGCTTAGAGTATGAGTTGCCATCTT
R-TTTGTATGTTTTCCAGACAACAGTAGC
4 UGT2B7 C802T F-GTAAATATCTGTGTCATC
R-GACTATAGAATCATTTCTACTG
5 UGT1A7 T622C F-GTGCCCTGCTCCTCTTTCCTAT
R-ACGGGTTTGGGATACTCCAAA
6 ABCB1/MDR1 C1236T F-GAAGAGTGGGCACAAACCAGATA
R-CATCCCCTCTGTGGGGTCATA
7 ABCB1/MDR1 C3435T F-GAGCCCATCCTGTTTGACTG
R-GCATGTATGTTGGCCTCCTT
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Table 3
Demographics, clinical and pharmacokinetic data (mean ± standard deviation). Data represent 27 small vessel
vasculitis and 19 lupus nephritis prospective patients (total n=46). Data provided as mean (SD); range
Parameter Data
Age (years) 46.0 (15.0); 22–78
Race (white/black/other) 27/13/6
Gender (male/female) 15/31
Weight (kg) 85.1 (19.7); 47–124
eClCr (mL/min) 93.4 (46.3); 18–185
UP:Cr 0.76 (1.48); 0–7.9
Serum albumin (g/L) 40.9 (50.2); 26–52
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Table 4
Pharmacokinetics of mycophenolic acid and metabolites in glomerulonephritis
MPA total(n=46) MPA free(n=46) MPAG(n=46) AcMPAG(n=41)
Cmax (μg/mL)a 20.9 (17.9) 0.30 (0.39) 63.9 (50.2) 0.91 (1.08)
Tmax (h) 1.46 (1.48) N/A 3.02 (2.54) 1.68 (1.65)
Ctr (μg/mL)a 4.11 (4.46) 0.07 (0.11) 31.7 (27.8) 0.28 (0.63)
AUC 0–12 (μg · h/mL)a 66.3 (43.8) 1.07 (1.57) 498 (433) 3.88 (4.80)
Cl/F (mL/min) 305 (173) 31.7 (28.6)b N/A N/A
AUC 6–12 (μg · h/mL)a 24.1 (19.9) N/A 214 (191) 1.53 (2.12)
ClR/F (mL/min) 3.74 (4.70) N/A 46.5 (45.9) 45.9 (53.4)
Free fraction (%) 1.63 (1.49) N/A 12.3 (6.74) N/A
T ½ (h) 14.5 (18.7) N/A 16.9 (26.1) 10.4 (8.26)
AUC 6–12/AUC 0–12 % 35.4 (12.2) N/A 39.7 (41.9) 0.37 (0.14)
AcMPAG, acyl MPAG; AUC 0–12, area under the plasma concentration time curve from 0–12 h; AUC 6–12, area under the plasma concentration
time curve from 6–12 h; AUC 6–12/AUC 0–12, fraction of AUC due to enterohepatic recycling; Cl/F, oral clearance; ClR/F, renal clearance;
Cmax, maximum concentration in plasma after a dose; Ctr, minimum concentration in plasma after a dose; eClcr, estimated creatinine clearance;
MPA, mycophenolic acid; MPAG, mycophenolic acid glucuronide; N/A, not applicable; Tmax, time to maximum plasma concentration; T½, half
life
a
Data concerning MPA were dose-normalized
b
L/min
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Table 5
Genotype frequency distributions (frequency [n])
Small vessel vasculitis(n = 27) Lupus nephritis(n = 19)
UGT1A9
 G8A G/G 1.0 (27) 1.0 (19)
G/A 0 (0) 0 (0)
A/G 0 (0) 0 (0)
 C98T C/C 0.96 (26) 1.0 (19)
C/T 0.04 (1) 0 (0)
T/T 0 (0) 0 (0)
 C-2152T C/C 0.96 (26) 1.0 (19)
C/T 0.04 (1) 0 (0)
T/T 0 (0) 0 (0)
 T-275A T/T 0.96 (26) 1.0 (19)
T/A 0.04 (1) 0 (0)
A/A 0 (0) 0 (0)
UGT1A7a
 T622C T/T 0.46 (12) 0.47 (9)
T/C 0.54 (14) 0.47 (9)
C/C 0 (0) 0.06 (1)
UGT2B7a
 C802T C/C 0.31 (8) 0.47 (9)
C/T 0.42 (11) 0.37 (7)
T/T 0.27 (7) 0.16 (3)
ABCB1/MDR1
 C1236T C/C 0.37 (10) 0.53 (10)
C/T 0.48 (13) 0.47 (9)
T/T 0.15 (4) 0 (0)
 C3425T C/C 0.33 (9) 0.37 (7)
C/T 0.52 (14) 0.58 (11)
T/T 0.15 (4) 0.05 (1)
ANCA, anti-neutrophil cytoplasmic antibody
a
Genotyping results missing in one ANCA vasculitis patient
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Table 6
Final univariate models for the separate effects of clinical, demographic, and genotype parameters on the
prediction of pharmacokinetic outcomes
Dependent variable a Independent variable Coefficient Model p Model R2
Clinical and demographic factors
 Mycophenolic acid
  Cmax Albumin 0.4902 0.0280 0.1051
Steroid Dose 0.0485 0.0261 0.1151
  Ctr Age 0.0191 0.0193 0.1182
Race 0.4924 0.0478 0.0861
Albumin 0.4940 0.0384 0.0939
UP:Cr −0.2128 0.0099 0.1416
Scr 0.6891 <0.0001 0.3218
eClcr −0.0098 0.0004 0.2527
  AUC 0–12 SCr 0.4261 0.0004 0.2490
Age 0.0114 0.0494 0.0850
Albumin 0.3690 0.0272 0.1060
eClcr −0.0066 0.0006 0.2372
UP:Cr −0.1558 0.0070 0.1537
  AUC 6–12 UP:Cr −0.2292 0.0010 0.2219
SCr 0.5980 <0.0001 0.3271
eClcr −0.0078 0.0010 0.2193
  Cl/F Age −0.0127 0.0305 0.1020
Albumin −0.3733 0.0287 0.1041
UP:Cr 0.1595 0.0069 0.1546
SCr −0.4250 0.0006 0.2377
eClcr 0.0072 0.0003 0.2642
Weight 0.0075 0.0989 0.0607
  ClR/F Weight 0.0221 0.0225 0.1152
  Cl unb eClcr 0.0071 0.0326 0.1066
  AUC unb eClcr −0.0068 0.0397 0.0991
  Ctrunb Scr 0.5738 0.0156 0.1343
eClcr −0.0086 0.0276 0.1129
 Mycophenolic acid glucuronide
  AUC 0–12 Age 0.0183 0.0325 0.0998
Caucasian 0.6100 0.0175 0.1216
UP:Cr −0.1779 0.0415 0.0911
SCr 0.5059 0.0059 0.1596
  AUC 6–12 Age 0.0181 0.0396 0.0928
Caucasian 0.6143 0.0200 0.1169
UP:Cr −0.1834 0.0407 0.0918
SCr 0.5960 0.0014 0.2100
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Dependent variable a Independent variable Coefficient Model p Model R2
eClcr −0.0077 0.0108 0.1386
  ClR/F Age −0.0204 0.0402 0.0943
SCr −0.6148 0.0030 0.1869
eClcr 0.0084 0.0181 0.1232
Female 0.6003 0.0518 0.0851
 Acyl-mycophenolic acid glucuronide
  AUC 0–12 Age 0.0437 0.0009 0.2497
Caucasian 0.9104 0.0311 0.1137
Albumin 1.0663 0.0093 0.1611
UP:Cr −0.2927 0.0311 0.1137
eClcr −0.0182 <0.0001 0.3487
  AUC 6–12 Age 0.0298 0.0067 0.1780
UP:Cr −0.2361 0.0282 0.1205
Scr 0.9490 <0.0001 0.3375
eClcr −0.0160 <0.0001 0.4347
  ClR/F Age −0.0320 0.0159 0.1473
Albumin −1.0760 0.0054 0.1913
eClcr 0.0130 0.0045 0.1981
Genotype factors
 Mycophenolic acid
  Cl/F UGT1A7 heterozygote 0.3508 0.0462 .0877
UGT2B7 heterozygote 0.3778 0.0355 0.0966
  AUC 0–12 UGT2B7 heterozygote −0.3702 0.0354 0.0967
  AUC 6–12 UGT2B7 heterozygote −0.4844 0.0240 0.1105
UGT2B7 variant/variant 0.5968 0.0185 0.1198
  Cmax UGT1A7 heterozygote −0.4647 0.0432 0.0897
  ClR/F UGT2B7 heterozygote 1.1748 0.0022 0.1974
UGT2B7 variant/variant −0.9237 0.0456 0.0897
 Acyl-mycophenolic acid glucuronide
  ClR/F UGT2B7 heterozygote 0.8323 0.0408 0.1083
Clunb, unbound oral clearance; Cmaxunb, unbound maximum concentration in plasma after a dose; Cmax, maximum concentration in plasma
after a dose; Ctr, minimum concentration in plasma after a dose; Ctrunb, unbound minimum concentration in plasma after a dose; Scr, serum
creatinine
a
The natural logarithmic transformation was used for all dependent variables except for acyl MPAG MR
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Table 7
Final multivariable linear models of the combined effects of genotype, clinical, and demographic parameters
on pharmacokinetics
Dependent parametersa Independent parameters (p value) Coefficient Model p value Model R2
Mycophenolic acid
 Ctr Caucasian race (0.008) 0.5384 <0.0001 0.4244
Scr (<0.0001) 0.7074
 AUC 0–12 UP:Cr (0.008) −0.1346 <0.0001 0.3622
Scr (0.0005) 0.3925
 AUC 6–12 UP:Cr (0.0005) −0.1996 <0.0001 0.4931
Scr (<0.0001) 0.5482
 Cl/F (1) UP:Cr (0.0084) 0.1384 <0.0001 0.3526
Scr (0.0008) −0.3905
 Cl/F (2) Weight (0.0143) 0.0090 <0.0001 0.4397
UP:Cr (0.0053) 0.1387
Scr (0.0002) −0.4153
 ClR/F Weight (0.0382) 0.0185 0.0011 0.2763
UGT2B7 Het (0.0039) 1.0715
Mycophenolic acid glucuronide
 AUC 0–12 Caucasian race (0.0063) 0.6443 0.0005 0.2950
SCr (0.0022) 0.5280
 AUC 6–12 Caucasian race (0.0052) 0.6544 0.0001 0.3420
SCr (0.0004) 0.6182
 ClR/F Female gender (0.0425) 0.5703 0.0016 0.2636
SCr (0.0027) −0.6012
Acyl-mycophenolic acid glucuronide
 AUC 0–12 Caucasian race (0.0100) 0.8772 <0.0001 0.4542
eClCr (<0.0001) −0.0182
 AUC6–12 Age (0.0408) 0.0197 <0.0001 0.4092
SCr (0.0005) 0.8193
 ClR/F Albumin (0.0030) −0.9947 <0.0001 0.4239
SCr (<0.0005) −0.09506
a
The natural logarithmic transformation was used for all dependent variables except AcylMPAG AUC0–12. Box–Cox transformation was used for
AcylMPAG AUC0–12 (lambda=0.2)
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